Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
Cardiomyopathy, Hypertrophic
About this trial
This is an observational trial for Cardiomyopathy, Hypertrophic focused on measuring Cardiac Hypertrophy, Drug-Refractory, Hemodynamic Benefits, Obstruction, Pacemaker Therapy, Hypertrophic Cardiomyopathy
Eligibility Criteria
Group 1: HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at the NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms. Group 2: HCM patients selected from Group 1 who at the follow-up cardiac catheterization are demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT obstruction (greater than 50% reduction in LVOT gradient). Patient who have developed a heart block will be excluded from group 2. Females must have a negative pregnancy test.
Sites / Locations
- National Heart, Lung and Blood Institute (NHLBI)